Rusfertide: complete guide

Rusfertide is a synthetic cyclic peptide that mimics hepcidin, approved by FDA as Mimrylo in 2026 for polycythemia vera. This guide covers its structure, mechanism, trials and warnings.

Complete guide5 min read

Key takeaway

FDA approved rusfertide as Mimrylo on August 28, 2026, number 36 on FDA’s novel drug approvals list for 2026. Its molecular weight is 2,442.0 for the free base. In the phase 3 VERIFY trial, 76.9% of patients on Mimrylo responded, versus 32.9% on placebo.

At a glance

Article typeComplete guide
On Rusfertide1 more article
Regulatory statusFDA-approved“FDA approved rusfertide as Mimrylo on August 28, 2026.” (this article)
ClassHeart & blood
Body systemsHeart & vessels
Studies cited2 in this article · 2 across 2 articles on Rusfertide
Related productsResearch peptide catalog

Rusfertide is a synthetic cyclic peptide that mimics hepcidin, the hormone that controls how much iron reaches the blood. By limiting iron, it slows the overproduction of red blood cells in polycythemia vera. This guide covers its structure, mechanism, labeled use, trials and label warnings. Sources were checked on November 17, 2026.

Quick answer: Rusfertide is a prescription hepcidin mimetic sold as Mimrylo by Takeda. Its label covers erythrocytosis, too many red blood cells, in adults with polycythemia vera. It has no boxed warning. Label warnings cover rising platelet counts, site reactions and possible harm to a fetus.

Vitrapep does not sell rusfertide; this page is a reference summary of published research and regulatory information.

What is rusfertide?

The Mimrylo label describes rusfertide as “a hepcidin mimetic” that “is a synthetic cyclic peptide (disulfide) isolated as an acetate salt.” It gives the free-base formula as C114H181N27O28S2 and the average molecular weight as 2442.0 u (Mimrylo label, 2026). PubChem lists the same formula and weight (PubChem CID 155884410).

“Cyclic” means the chain is closed into a ring, here by a disulfide bond between two sulfur atoms. Hepcidin itself is a natural peptide hormone; NCI Thesaurus text in PubChem calls rusfertide a peptide mimetic of hepcidin. Our guides to types of peptides and peptide hormones give background.

FDA’s novel drug approvals list records Mimrylo (rusfertide) as approved on August 28, 2026 (FDA, 2026a). Our news report on the rusfertide approval covers the announcement itself.

Table 1

Rusfertide: key facts

Fact Detail
Structure type Synthetic cyclic peptide closed by a disulfide bond; acetate salt
Class Hepcidin mimetic (ferroportin blocker)
Molecular formula C114H181N27O28S2 (free base)
Molecular weight 2,442.0 (free base)
First FDA approval August 28, 2026 (Mimrylo; novel drug approval 36 of 2026)
Brand names (US) Mimrylo (Takeda Pharmaceuticals America)

How does rusfertide work?

Polycythemia vera is a rare blood disorder marked by overproduction of red blood cells. Making red cells takes iron. The label states that rusfertide “is a mimetic of the endogenous hormone hepcidin that blocks the iron transporter ferroportin.”

Ferroportin is an iron transporter. The label explains that blocking it “reduces availability of iron for production of red blood cells.” That lowers hematocrit, the share of blood made up of red cells (Mimrylo label, 2026). FDA calls it the first approved treatment for the disease that “mimics hepcidin, a hormone that naturally regulates iron in the body” (FDA, 2026b).

What is rusfertide approved for?

The Mimrylo label states: “MIMRYLO is indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV).”

FDA approved rusfertide as Mimrylo on August 28, 2026. FDA’s announcement names Takeda Pharmaceuticals America, Inc. as the company and says the application received priority review. FDA’s orphan drug database lists an orphan designation for polycythemia vera, granted June 12, 2020. Its exclusivity end date is shown as “TBD” (FDA, 2026c).

What did the key trials show?

VERIFY, phase 3. This randomized, double-blind, placebo-controlled human trial enrolled 293 adults with polycythemia vera who needed frequent phlebotomies, a procedure to remove blood. Patients stayed on their usual care, with or without cytoreductive drugs. They were randomized one to one to rusfertide or placebo for 32 weeks.

A responder was a patient who did not meet criteria for phlebotomy between weeks 20 and 32. The label reports 76.9% responders on Mimrylo and 32.9% on placebo (p < 0.0001). Hematocrit stayed below 45% in 62.6% versus 14.4%. The mean number of phlebotomies was 0.53 versus 1.82. The published report lists the same trial as 77% versus 33%, and notes no deaths (Kuykendall et al., 2026; NCT05210790).

REVIVE, phase 2. This earlier human trial enrolled 70 patients. In its blinded withdrawal part, 59 were randomized to keep taking rusfertide or switch to placebo. Response was 60% versus 17% (P = 0.002). During the open part, phlebotomies fell from 8.7 per year before treatment to 0.6 (Kremyanskaya et al., 2024; NCT04057040).

What side effects does the label list?

The Mimrylo label has no boxed warning. It lists the most common adverse reactions, each above 15%, as site reactions (56%) and anemia (16%). On placebo, the rates were 33% and 4.1%. Here, “site” means where the drug is given.

The label’s warnings cover three areas:

  • New or worsening thrombocytosis: “MIMRYLO may increase platelet counts in patients with PV.” Within 4 weeks of starting, platelet counts rose by an average of 31%.
  • Site reactions: reactions where the drug is given.
  • Embryo-fetal toxicity: based on animal studies, it may cause fetal harm.

FDA’s announcement also names site reactions and anemia as the most common side effects (FDA, 2026b).

What is rusfertide’s regulatory status, and how is it used in research?

Rusfertide is a prescription drug in the United States, approved for one use. Tanya Wroblewski, M.D., directs FDA’s Division of Nonmalignant Hematology. She called it “a new, first-in-class option that has the potential to meaningfully reduce patient burden” (FDA, 2026b).

Research continues in human studies. ClinicalTrials.gov lists THRIVE, a phase 3 long-term safety study, as active (NCT06033586). Takeda also lists phase 2 studies in adults in Japan and China (NCT07648030; NCT07765602). Protagonist Therapeutics ran earlier trials under the code PTG-300. We found no documented role as a laboratory reagent in the sources we checked.

Frequently asked questions about rusfertide

Is rusfertide a peptide?

Yes. Its label describes it as a synthetic cyclic peptide closed by a disulfide bond.

When was rusfertide approved?

FDA approved Mimrylo on August 28, 2026, for erythrocytosis in adults with polycythemia vera.

What is hepcidin?

Hepcidin is a natural hormone that regulates iron. Rusfertide copies its action, blocking ferroportin so less iron reaches the blood.

Did rusfertide reduce phlebotomies in trials?

Yes. In VERIFY, most patients on rusfertide no longer met criteria for phlebotomy between weeks 20 and 32. The mean number of phlebotomies fell to 0.53, versus 1.82 on placebo.

Does rusfertide have a boxed warning?

No. Its warnings cover rising platelet counts, site reactions and possible fetal harm.

What to know now

  • Structure: synthetic cyclic disulfide peptide; C114H181N27O28S2; 2,442.0 (free base).
  • Approval: Mimrylo, August 28, 2026; priority review; orphan designation.
  • Mechanism: hepcidin mimetic that blocks ferroportin and limits iron for red cells.
  • Label use: erythrocytosis in adults with polycythemia vera.
  • Evidence: 76.9% versus 32.9% responders in VERIFY.
  • Safety: no boxed warning; site reactions and anemia most common; watch platelets.

What we’re watching

Results from the THRIVE long-term safety study and from VERIFY, still listed as active. The orphan exclusivity end date once FDA lists it. Related guides: the rusfertide approval, peptide hormones and angiotensin II.

Everything on Rusfertide

More for heart & vessels

All 13 compounds for heart & vessels

Sources: Takeda Pharmaceuticals America 2026, MIMRYLO (rusfertide) prescribing information; U.S. Food and Drug Administration 2026a, Novel drug approvals for 2026; U.S. Food and Drug Administration 2026b, FDA approves first drug of its kind for polycythemia vera, a rare blood disorder; U.S. Food and Drug Administration 2026c, Search orphan drug designations and approvals: rusfertide; National Center for Biotechnology Information 2026, PubChem compound summary for CID 155884410, rusfertide; Kuykendall 2026, Journal of Clinical Oncology; Protagonist Therapeutics 2022, A study of rusfertide in adults with polycythemia vera (PV) (VERIFY); Kremyanskaya 2024, The New England Journal of Medicine, 390; Protagonist Therapeutics 2019, Hepcidin mimetic in patients with polycythemia vera (REVIVE); Protagonist Therapeutics 2023; Takeda 2026, A study of rusfertide in Japanese adults with polycythemia vera; Takeda 2026, A study of rusfertide in adults with polycythemia vera in China. All 12 citations

Back to the research library

References

  1. Takeda Pharmaceuticals America, Inc. (2026). MIMRYLO (rusfertide) prescribing information (revised 8/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=101aff01-31ed-4841-a8b6-0a5a8503189b
  2. U.S. Food and Drug Administration. (2026a). Novel drug approvals for 2026. Retrieved November 17, 2026, from https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
  3. U.S. Food and Drug Administration. (2026b, August 28). FDA approves first drug of its kind for polycythemia vera, a rare blood disorder. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder
  4. U.S. Food and Drug Administration. (2026c). Search orphan drug designations and approvals: rusfertide. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=715819
  5. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 155884410, rusfertide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/155884410
  6. Kuykendall, A. T., et al. (2026). VERIFY: A phase III trial of rusfertide versus placebo in phlebotomy-dependent patients with polycythemia vera receiving standard-of-care therapy. Journal of Clinical Oncology. Advance online publication. https://doi.org/10.1200/JCO-26-00992
  7. Protagonist Therapeutics, Inc. (2022). A study of rusfertide in adults with polycythemia vera (PV) (VERIFY) (ClinicalTrials.gov ID NCT05210790). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT05210790
  8. Kremyanskaya, M., et al. (2024). Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera. The New England Journal of Medicine, 390(8), 723-735. https://doi.org/10.1056/NEJMoa2308809
  9. Protagonist Therapeutics, Inc. (2019). Hepcidin mimetic in patients with polycythemia vera (REVIVE) (ClinicalTrials.gov ID NCT04057040). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04057040
  10. Protagonist Therapeutics, Inc. (2023). Study to evaluate the long-term safety of rusfertide (PTG-300) in subjects with polycythemia vera (THRIVE) (ClinicalTrials.gov ID NCT06033586). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT06033586
  11. Takeda. (2026). A study of rusfertide in Japanese adults with polycythemia vera (ClinicalTrials.gov ID NCT07648030). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT07648030
  12. Takeda. (2026). A study of rusfertide in adults with polycythemia vera in China (ClinicalTrials.gov ID NCT07765602). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT07765602